| Title |
Review of interferon beta-1b in the treatment of early and relapsing multiple sclerosis
|
|---|---|
| Published in |
Biologics: Targets & Therapy, July 2009
|
| DOI | 10.2147/btt.s4038 |
| Pubmed ID | |
| Authors |
Damiano Paolicelli, Vita Direnzo, Maria Trojano |
| Abstract |
Multiple sclerosis (MS) is the most common autoimmune illness of the central nervous system. For many years the inflammatory manifestations of MS were treated using only corticosteroids. Since the 1990s the results of several clinical trials with immunomodulatory agents have changed the therapeutic approach to this disease. Interferon beta (IFNbeta)-1b represents the pioneer of those therapies. There is growing evidence from clinical trials on relapsing-remitting MS and clinically isolated syndromes suggestive of MS that IFNbeta-1b reduces the frequency and severity of relapses and the development of new and active brain lesions as assessed by magnetic resonance imaging. Long-term data suggest a persistent efficacy of IFNbeta-1b on disease activity and a positive effect in slowing disability worsening. Furthermore a reduction of relapse rate and a slight positive effect on the progression were demonstrated when IFNbeta-1b was administered to still-active secondary progressive MS. IFNbeta-1b therapy is well tolerated and relatively free of long-term side effects. In spite of the emergence of new agents for the treatment of MS, IFNbeta-1b still remains a first-line therapy with a fundamental role in all stages of the disease. |
Mendeley readers
The data shown below were compiled from readership statistics for 54 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United Kingdom | 1 | 2% |
| Spain | 1 | 2% |
| Turkey | 1 | 2% |
| Unknown | 51 | 94% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Ph. D. Student | 13 | 24% |
| Student > Master | 10 | 19% |
| Student > Bachelor | 8 | 15% |
| Researcher | 6 | 11% |
| Professor > Associate Professor | 4 | 7% |
| Other | 7 | 13% |
| Unknown | 6 | 11% |
| Readers by discipline | Count | As % |
|---|---|---|
| Agricultural and Biological Sciences | 13 | 24% |
| Medicine and Dentistry | 13 | 24% |
| Biochemistry, Genetics and Molecular Biology | 5 | 9% |
| Immunology and Microbiology | 3 | 6% |
| Sports and Recreations | 3 | 6% |
| Other | 6 | 11% |
| Unknown | 11 | 20% |
Attention Score in Context
This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 22 January 2021.
All research outputs
#8,533,995
of 25,371,288 outputs
Outputs from Biologics: Targets & Therapy
#110
of 284 outputs
Outputs of similar age
#42,074
of 122,276 outputs
Outputs of similar age from Biologics: Targets & Therapy
#2
of 4 outputs
Altmetric has tracked 25,371,288 research outputs across all sources so far. This one is in the 43rd percentile – i.e., 43% of other outputs scored the same or lower than it.
So far Altmetric has tracked 284 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 6.2. This one is in the 46th percentile – i.e., 46% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 122,276 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 18th percentile – i.e., 18% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 4 others from the same source and published within six weeks on either side of this one. This one has scored higher than 2 of them.